A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC)

Lung Cancer

Volumn 57, Issue 2, 2007, Pages 181-186

  Laack, Eckart ^a   Thöm, Ina ^a   Krüll, Andreas ^a   Engel Riedel, Walburga ^b   Müller, Thomas ^c   Meißner, Christoph ^d   Dürk, Heinz ^e   Fischer, Jürgen ^f   Gütz, Sylvia ^g   Kortsik, Cornelius ^h   Elbers, Matthias ⁱ   Schuch, Gunter ^a   Andritzky, Birte ^a   Görn, Michael ^a   Burkholder, Iris ^j   Edler, Lutz ^j   Hossfeld, Dieter Kurt ^a   Bokemeyer, Carsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Hospital Merheim   (Germany)

^c Hospital Hofheim   (Germany)

^d Hospital Marienhof Koblenz   (Germany)

^e Marien Hospital Hamm   (Germany)

^f Hospital Löwenstein   (Germany)

^g Klinikum St Georg   (Germany)

^h St Hildegardis Krankenhaus   (Germany)

ⁱ Marien Hospital Soest   (Germany)

^j GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

Carboplatin; Irinotecan; Limited disease; Phase II study; Small cell lung cancer

Indexed keywords

CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, SMALL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34447254077     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.03.001     Document Type: Article

References (22)

1. Elias A.D., Ayash L., Frei E., Skarin A.T., Hunt M., Wheeler C., et al. Intensive combined modality therapy for limited-disease small cell lung cancer. J Natl Cancer Inst 85 (1993) 559-566
2. Hanna N.H., and Einhorn L. Small cell lung cancer: state of the art. Clin Lung Cancer 4 (2002) 87-94
3. Mascaux C., Paesmans M., Berghmans T., Branle F., Lafitte J.J., Lemaitre F., et al., European Lung Cancer Working Party (ELCWP). A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30 1 (2000) 23-36
4. Niell H.B., Herndon II J.E., Miller A.A., Watson D.M., Sandler A.B., et al., Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small cell lung cancer: Cancer and Leukemia Group B trial 9732. J Clin Oncol 23 16 (2005) 3752-3759
5. Dy G.K., Miller A.A., Mandrekar S.J., Aubry M.C., Langdon Jr. R.M., Morton R.F., et al. A phase II trial of imatinib (STI 571) in patients with c-kit expressing relapsed small cell lung cancer: a CALGB and NCCTG study. Ann Oncol 16 11 (2005) 1811-1816
6. Moore A.M., Einhorn L.H., Estes D., Govindan R., Axelson J., Vinson J., et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell lung cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 52 1 (2006) 93-97
7. Fukuoka M., Furuse K., Saijo N., Nishiwaki Y., Ikegami H., Tamura T., et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 83 (1991) 855-861
8. Ueoka H., Kiura K., Tabata M., Kamei H., Gemba K., Sakae K., et al. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristin (CAV)/cisplatin and etoposide (PVP) versus sequential administration of VAV-PVP for the treatement of patients with small cell lung carcinoma: results of long term follow up. Cancer 83 (1998) 283-290
9. Murray N., Livingston R.B., Shephard F.A., James K., Zee B., Langleben A., et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small cell lung cancer: an intergroup study of NCI-Canada CTG and SWOG. J Clin Oncol 17 (2001) 2300-2308
10. Wolf M. Dose intensive chemotherapy in small cell lung cancer. Lung Cancer 33 1 (2001) 125-135
11. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al., Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 346 (2002) 85-91
12. Hanna N., Bunn Jr. P.A., Langer C., Einhorn L., Guthrie Jr. T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin (EP) in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 (2006) 2038-2043
13. Stahel R.A., Ginsberg R., and Havemann K. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5 (1989) 119-126
14. Therasse P., Le Cesne A., Van Glabbeke M., Verweij J., and Judson I. RECIST versus WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer 41 10 (2005) 1426-1430
15. Simon R. Optimal two-stage designs for phase II clinical trials. Ctrl Clin Trials 10 (1989) 1-10
16. Schmittel A., Schulze K., Hütter G., Krebs P., Thiel E., and Keilholz U. Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer. Onkologie 27 (2004) 280-284
17. Schmittel A., Fischer von Weikersthal L., Sebastian M., Partus P., Schulze K., Hortig P., et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small cell lung cancer. Ann Oncol 17 4 (2006) 663-667
18. Kinoshita A., Fukuda M., Soda H., Nagashima S., Fukuda M., Takatani H., et al., Nagasaki Thoracic Oncology Group (NTOG). Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. Br J Cancer 94 (2006) 1267-1271
19. Sohn J.H., Choi H.J., Chang J., Kim S.K., Lee C.G., Chung K.Y., et al. A phase II trial of fracionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. Lung Cancer 54 3 (2006) 365-370
20. Okamoto H., Naoki K., Narita Y., Hida N., Kunikane H., and Watanabe K. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. Lung Cancer 53 2 (2006) 197-203
21. Hirose T., Horichi N., Ohmori T., Ogura K., Hosaka T., Ando K., et al. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer 40 3 (2003) 333-338
22. Naka N., Kawahara M., Okishio K., Hosoe S., Ogawara M., Atagi S., et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 37 3 (2002) 319-323